Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aileron Therapeutics, Inc. ALRN
$1.45
-$0.04 (-2.68%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
6902578.00000000
-
week52high
9.60
-
week52low
1.12
-
Revenue
0
-
P/E TTM
0
-
Beta
2.00657400
-
EPS
-5.64000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 10:59
Описание компании
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 30 июн 2022 г. |
| William Blair | Market Perform | Outperform | 29 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 июн 2020 г. |
| H.C. Wainwright | Buy | Buy | 31 мар 2020 г. |
| Canaccord Genuity | Buy | Buy | 09 апр 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Morrison Jodie Pope | A | 54500 | 54500 | 15 июн 2022 г. |
| VON RICKENBACH JOSEF H | A | 54500 | 54500 | 15 июн 2022 г. |
| MCKEE WILLIAM | A | 54500 | 54500 | 15 июн 2022 г. |
| Bailey Jeffrey Allen | A | 54500 | 54500 | 15 июн 2022 г. |
| Ambros Reinhard J. | A | 54500 | 54500 | 15 июн 2022 г. |
| Sigal Nolan Howard | A | 54500 | 54500 | 15 июн 2022 г. |
| Annis Allen | A | 313000 | 313000 | 30 мар 2022 г. |
| Wanstall Rick | A | 393000 | 393000 | 30 мар 2022 г. |
| Vukovic Vojo | A | 150000 | 150000 | 30 мар 2022 г. |
| Aivado Manuel | A | 1133000 | 1133000 | 30 мар 2022 г. |
Новостная лента
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
Zacks Investment Research
04 апр 2023 г. в 11:24
After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks Investment Research
14 мар 2023 г. в 11:26
Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
Zacks Investment Research
29 дек 2022 г. в 13:32
Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
04 ноя 2022 г. в 13:34
Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
GlobeNewsWire
22 сент 2022 г. в 08:00
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in New York, New York.